EN DE

Ma Kuang Healthcare Holding (4139) Fair Value & Analysis

Healthcare · TW · Market cap 1.9B TWD

MK Ma Kuang Healthcare Holding 4139 · TWO
Price36.40 TWD
Fair Value50.82 TWD
Upside+39.6%
Quality48/100
Watch Ma Kuang Healthcare Holding for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -7.3% net margin
Low debt · generates free cash flow
Trails peers (4/12)
Narrow moat 13/100
Evidence: Medium Range 39.88 TWD – 69.67 TWD Share as image

Fair value as of: Jul 23, 2026

From 13 valuation models · updated 18 days ago

Share price +46.2% over the past month.

Below-average quality, screening 40% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (39.88 TWD). The market is more pessimistic than our downside scenario.
  • Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

56.61 TWD 21.85 TWD Fair Value 50.82 TWD Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 21.85 TWD – 56.61 TWD · fair‑value band 39.88 TWD – 69.67 TWD · the 36.40 TWD price screens below the 50.82 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Ma Kuang Healthcare Holding (4139) currently trades at 36.40 TWD, while our model-based Fair Value estimate is 50.82 TWD, implying the stock looks roughly 39.6% undervalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Ma Kuang Healthcare Holding generated revenue of 1.1B TWD at a net margin of -7.3%. Revenue declined 3.6% year over year. It earns a return on equity of -19.6%. Net debt stands at 286M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 39.88 TWD (bear case) to 69.67 TWD (bull case); at 36.40 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 73% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 40%, 4139 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 40.14 TWD 50.67 TWD 67.86 TWD 80
Rev-Margin DCF 39.33 TWD 57.36 TWD 79.95 TWD 74
Gordon GGM 11.75 TWD 13.01 TWD 14.57 TWD 70
All 13 models by family
DCF Models
FCF DCF 38.99 TWD 50.03 TWD 69.67 TWD 38
Owner Earnings 20.09 TWD 25.81 TWD 35.99 TWD 31
5Y Revenue Exit 39.33 TWD 56.34 TWD 81.59 TWD 39
5Y EBITDA Exit 39.29 TWD 56.27 TWD 79.25 TWD 41
10Y Revenue Exit 37.93 TWD 50.82 TWD 64.96 TWD 36
10Y EBITDA Exit 38.88 TWD 50.77 TWD 63.64 TWD 37
Dividend Discount
Gordon GGM 11.75 TWD 13.01 TWD 14.57 TWD 70
DDM Multi-Stage 11.75 TWD 14.45 TWD 17.62 TWD 61
Multiples
EV/EBITDA 46.00 TWD 61.40 TWD 76.81 TWD 54
EV/Revenue 43.00 TWD 61.52 TWD 80.05 TWD 43
Asset-Based
NCAV (Graham) 4.91 TWD 6.58 TWD 9.82 TWD 50
Growth DCF
Growth DCF 40.14 TWD 50.67 TWD 67.86 TWD 80
Rev-Margin DCF 39.33 TWD 57.36 TWD 79.95 TWD 74

Widest divergence: Multiples (61.40 TWD) versus Asset-Based (6.58 TWD). Highest evidence: Growth DCF (80).

Notify me when 4139 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 1.1B TWD
Revenue growth (YoY) -3.6%
Net margin -7.3%
Return on equity -19.6%
Free cash flow 214M TWD FY2025
Operating margin -8.6%
More key figures
EPS (TTM) -1.55 TWD
EPS growth (YoY) -20.0%
Net debt 286M TWD FY2025

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 48/100

Of which business quality 50 · Market factors (momentum, volatility) 73

Profitability 15
Margins and returns on capital today
Quality Growth 39
Are margins and returns improving?
Cashflow 83
Earnings quality: real cash, not paper profit
Fin. Strength 39
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 77
Calm price path (market factor)
Momentum 72
Price trend over the last 3–12 months (market factor)
52W Momentum 69
Distance to the 52-week high (market factor)
Net Issuance 43
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Ma Kuang Healthcare Holding Limited, an investment holding company, provides medical services in Taiwan, Singapore, Mainland China, and internationally. The company offers community medical services, Chinese medical services, Chinese medicines, medical management training courses, educational support services, etc.

Full company description

Ma Kuang Healthcare Holding Limited, an investment holding company, provides medical services in Taiwan, Singapore, Mainland China, and internationally. The company offers community medical services, Chinese medical services, Chinese medicines, medical management training courses, educational support services, etc. It also provides medical treatment, and overseas student homestay and guardianship services; management consultant services; Chinese medicine beauty services; consulting services, such as corporate management, computer technology, industry information, and marketing; and e-commerce sales services. In addition, the company operates clinics, educational institutions, community medicine clinics, and traditional Chinese medicine clinics. Further, it is involved in sale of dietary supplement, and pharmaceutical and medical goods in stores; restaurant business; and leasing and other services. The company was incorporated in 2009 and is based in Kaohsiung, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Ma Kuang Healthcare Holding reported revenue of 1.1B TWD in FY2025 versus 959M TWD in FY2021, a compound +3.3%/yr. Reported net income was −67.1M TWD in FY2025.

Growth Quality 37/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
1.1B TWD
Latest YoY
−3.3%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.1%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.7%
Avg. growth/yr (10Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.2%
Revenue +3.3%/yr
FY21 959M TWD
FY22 1.1B TWD
FY23 1.2B TWD
FY24 1.1B TWD
FY25 1.1B TWD
Net income
FY21 38.5M TWD
FY22 −30.9M TWD
FY23 −42.5M TWD
FY24 10.3M TWD
FY25 −67.1M TWD

Watch 4139: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Ma Kuang Healthcare Holding Fair Value". https://www.fairvalue-calculator.com/stock/4139

Peer Group

Medical Care Facilities · 261 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 48 · Below median
Fair Value upside +40% · Top 25%
Return on assets -2% · Bottom 25%
Net margin (TTM) -7% · Bottom 25%
Operating margin (TTM) -9% · Bottom 25%
Revenue growth -4% · Bottom 25%
Debt / equity 0.31× · Higher than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/B 0.13× · Cheaper than 75% of peers
P/S (TTM) 0.05× · Cheaper than 75% of peers
P/FCF 0.3× · Cheaper than 75% of peers
EV/EBITDA 37.1× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 86 · sector 23
FUTURE 0 · sector 24
PAST 0 · sector 30
HEALTH 85 · sector 90
DIVIDEND 0 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare Ma Kuang Healthcare Holding with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Ma Kuang Healthcare Holding (4139) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 50.82 TWD versus a price of 36.40 TWD, about +40% (undervalued).
What is the fair value of 4139?
Our model-based fair value for Ma Kuang Healthcare Holding is 50.82 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 36.40 TWD.
What is the quality score of 4139?
Ma Kuang Healthcare Holding has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Ma Kuang Healthcare Holding (4139)?
Ma Kuang Healthcare Holding reported trailing-twelve-month revenue of about 1.1B TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 4139?
The net profit margin of Ma Kuang Healthcare Holding is about -7.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Ma Kuang Healthcare Holding and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.